Novel deep-learning approach for predicting and explaining the key prognostic factors for patients with Mesothelioma Paris, France and New York, USA, October 7th, 2019 – Owkin, which is developing machine learning technologies to advance medical research, today announces publication of a paper in Nature Medicine that showcases its breakthrough analysis of tumour biology using interpretable […]
Calliditas Therapeutics AB (publ) (“Calliditas”) today announced that the European Medicines Agency (EMA) has provided positive guidance related to a conditional marketing authorization (CMA) of the company’s lead compound Nefecon, currently in Phase 3 clinical trials in IgA nephropathy (IgAN). In a written response received from EMA, the agency agreed that it could support CMA […]
Cambridge, UK and New York, US, 24 September 2019. Artios Pharma Limited (Artios), a leading DNA Damage Response (DDR) company developing a broad pipeline of innovative treatments for cancer, today announces the appointment of Tania Dimitrova as Chief Business Officer and its expanded presence in the United States. Tania is based at Artios’s new offices […]
Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the central nervous system (CNS), today provides a business update for the last twelve months. Following the rebranding of the company in October 2018 to Neuraxpharm from NuPharm Group, Neuraxpharm has made great strides to build a sustainable business in the past year, delivering […]
Guildford, UK – 06 February 2019: HOX Therapeutics, the private biotechnology company developing first-in-class, highly targeted cancer therapies based on HOX genes, announces today that it will present a poster entitled “Targeting of HOX-PBX binding in glioblastoma multiforme as a novel therapeutic treatment” at the American Association for Cancer Research Annual Meeting 2019 in Atlanta, […]
